Lumos Pharma Inc

Lumos Pharma — Technical Presentation (December 2022)

42 slides from Lumos Pharma's technical presentation, Dec 12, 2022

  1. Slide 1: KOL Event December 6, 2022

    1 KOL Event December 6, 2022

  2. Slide 2: Forward Looking Statements

    2 Forward Looking Statements This presentation contains proprietary and confidential information of Lumos Pharma, Inc. (“Lumos,” “we,” “us” and “our”), and such content should be considered “Confidential Information” and covered by your confidentiality obligations to Lumos. This presentation is made

  3. Slide 3: Investment Highlights

    3 Investment Highlights Lead asset targeting children with growth disorders PGHD = Pediatric Growth Hormone Deficiency * USA, Germany, France, Italy, Spain, UK, Japan (Grandview Research, Growth Hormone Market Forecast, 2019) Novel Oral Rare Disease Asset Pipeline in a Product Solid Financial Positi

  4. Slide 4: Key Opinion Leaders in the Field of Pediatric Endocrinology

    4 Key Opinion Leaders in the Field of Pediatric Endocrinology Andrew Dauber, M.D., M.M.Sc., is the Chief of Endocrinology at Children’s National Hospital, specializing in growth disorders. Dr. Dauber has served as the program director and director of translational research at the interdisciplinary C

  5. Slide 5: Andrew Dauber, M.D., M.M.Sc. OraGrowtH210 Trial

    Andrew Dauber, M.D., M.M.Sc. OraGrowtH210 Trial

  6. Slide 6: Review of Interim Data for Phase 2 OraGrowtH210 Trial

    Review of Interim Data for Phase 2 OraGrowtH210 Trial Andrew Dauber, MD MMSc Chief of Endocrinology Children’s National Hospital Evaluation of Oral LUM-201 in Moderate Idiopathic Pediatric Growth Hormone Deficiency (PGHD) 6

  7. Slide 7: Disclosures

    Disclosures • Consulting fees or speaker honoraria: – Ascendis, OPKO, BridgeBio, Novo Nordisk, Pfizer, Ipsen, Sandoz • Prior Research Support – Novo Nordisk, Ipsen, Pfizer • Current Research Support – BioMarin, NICHD, Pfizer • Site Investigator in Lumos OraGrowth210 Trial 7

  8. Slide 8: LUM-201 – Oral Growth Hormone Secretagogue

    LUM-201 –Oral Growth Hormone Secretagogue https://lumos-pharma.com/posters-publications/ ClinicalTrials.gov NCT04614337. LUM-201 • Binds to GH Secretagogue (ghrelin) receptor • Increases amplitude of endogenous GH pulses • Acts within intact GH/IGF-1 feedback loop • Phase 2 study ongoing • 3 doses o

  9. Slide 9: Single Stim Dose of LUM-201 Identifies Likely Responders

    Single Stim Dose of LUM-201 Identifies Likely Responders Responders to LUM-2012 Non-Responders to LUM-201 Moderate / Idiopathic PGHD PEM-Positive ~60% of total PGHD population1 Severe / Organic PGHD PEM-Negative ~40% of total PGHD population Predictive Enrichment Marker Positive (PEM+) • Baseline IG

  10. Slide 10: Phase 2 OraGrowtH210 Trial in Moderate Idiopathic PGHD

    Phase 2 OraGrowtH210 Trial in Moderate Idiopathic PGHD n = 20 Daily rhGH injection n = 20 LUM-201: 3.2 mg/kg/day n = 20 LUM-201: 1.6 mg/kg/day n = 20 LUM-201: 0.8 mg/kg/day R a n d o m i z a t i o n Trial Design ❖ N = 80 subjects ❖ Only PEM(+) PGHD subjects ❖ Inclusion: stim GH > 5 ng/mL* & baseline

  11. Slide 11: Historical Data for rhGH Growth Rates in Moderate PGHD

    Historical Data for rhGH Growth Rates in Moderate PGHD rhGH 0204 rhGH GeNeSIS1 rhGH iPGHD2 rhGH KIGS3 0 4 8 12 16 20 n=3075 8.58 n=100 8.30 n=433 8.29 n=11 8.80 A n n u a li z e d H e ig h t V e lo c it y ( c m /y r) Historical Datasets • GeNeSIS1, iPGHD2, and KIGS3 AHV at 12 months on rhGH • Merck

  12. Slide 12: OraGrowtH210 Interim Analysis: AHV at 6 Months (41 Subjects)

    OraGrowtH210 Interim Analysis: AHV at 6 Months (41 Subjects) Interim Results • 1.6 mg/kg/day LUM-201 cohort growth of 8.6 cm/year was in line with the expected rate of 8.3-8.5 cm/year based on historical data • rhGH cohort grew at a much faster rate than expected or previously reported in moderate i

  13. Slide 13: OraGrowtH210 Baseline Characteristics at Interim (n=41)

    OraGrowtH210 Baseline Characteristics at Interim (n=41) LUM-201 0.8 mg Mean (SD) N=11 LUM-201 1.6 mg Mean (SD) N=10 LUM-201 3.2 mg Mean (SD) N=10 rhGH Mean (SD) N=10 Age (months) 95.5 (28.2) 99.3 (28.3) 96.1 (21.7) 90.3 (26.7) Height (cm) 113.8 (12.6) 114.6 (9.6) 113.8 (8.8) 111.6 (11.9) Height SDS

  14. Slide 14: Growth Outliers in the rhGH Cohort

    Growth Outliers in the rhGH Cohort: Two of Three Subjects Under Age 5 Randomized to rhGH 1 Ranke, et al 2010 JCEM P lines = Percentiles “Before” line marks height velocity before GH therapy First-year Growth on rhGH for Pfizer’s Moderate PGHD KIGS Database Analysis1 OraGrowtH210 youngest subjects in

  15. Slide 15: Interim OraGrowtH210 Data: LUM-201 Demonstrates Durable Response to 12 Months

    Interim OraGrowtH210 Data: LUM-201 Demonstrates Durable Response to 12 Months 0.8 1.6 3.2 rhGH 0 4 8 12 16 20 7 10.46 6 6.80 6 8.48 5 6.17 A n n u a li z e d H e ig h t V e lo c it y ( c m /y r) 9-month AHV mg/kg LUM-201 Conclusions • Growth rates for LUM-201 are consistent from 6 to 12 months • A P

  16. Slide 16: Safety Profile at Interim Analysis for OraGrowtH210 Trial

    Safety Profile at Interim Analysis for OraGrowtH210 Trial 0.8 mg/kg 1.6 mg/kg 3.2 mg/kg ALL LUM-201 rhGH 34 mcg/kg N = 14 15 14 43 15 Number of AEs 31 45 38 114 21 Subjects with AE (%) 8 (57.1%) 13 (86.7%) 9 (64.3%) 30 (69.8%) 9 (60.0%) Treatment Related AEs (N) 2 1 3 6 3 Subjects with Treatment Rel

  17. Slide 17: Summary of Interim OraGrowtH210 Data

    Summary of Interim OraGrowtH210 Data • Growth of 8.6 cm/yr on 1.6 mg LUM-201 in line with expectations • 9 and 12-month growth data look encouraging for LUM-201, but N is small • Interim safety data appear comparable to rhGH treatment 17

  18. Slide 18: Fernando Cassorla, M.D. OraGrowtH212 Trial

    Fernando Cassorla, M.D. OraGrowtH212 Trial

  19. Slide 19: Effects of the oral GH secretagogue LUM-201 on pulsatile GH secretion and linear growth

    Fernando Cassorla MD Chief of Pediatric Endocrinology Institute of Maternal and Child Research University of Chile, Santiago, Chile Effects of the oral growth hormone (GH) secretagogue LUM-201 (Ibutamoren) on pulsatile GH secretion and linear growth in children with moderate GH deficiency 19

  20. Slide 20: Disclosure

    Disclosure Fernando Cassorla M.D. Dr. Cassorla is an investigator for clinical studies with LUM-201 at the University of Chile and has previously acted as a consultant for Debiopharm, Novo Nordisk, Pfizer, Merck and Sandoz. LUM-201 is an investigational compound and is not approved for use by the FD

  21. Slide 21: Questions regarding the effects of LUM-201 in pediatric patients

    ▪ Does the oral administration of LUM-201 at the doses of 1.6 mg/kg or 3.2 mg/kg for 6 months increase height velocity? ▪ Is the change in height velocity correlated with changes in GH pulsatility? ▪ Is the increase in GH pulsatility and height velocity induced by LUM-201 dose dependent? Questions r

  22. Slide 22: Design of the OraGrowtH212 clinical PK/PD study of LUM-201

    • 24 prepubertal patients between the ages of 4 to 8 years (girls) and 10 years (boys) with short stature caused by moderate idiopathic PGHD, and naïve to GH treatment, will be randomized to receive oral LUM-201 at a dose of 1.6 mg/kg/day (n:12) or 3.2 mg/kg/day (n:12) • Pulsatile GH secretion has b

  23. Slide 23: OraGrowtH212 Trial

    LUM-201 1.6 mg/kg/day N=12 Screening Baseline 6 months Height Height IGF-1 IGF-1 Q10m 12h GH Q10m 12h GH Inclusion Criteria: Height < 2 SD, delayed bone age, serum IGF-1 below the mean for age, and a peak GH response to a clonidine stimulation test between 3 and 10 ng/mL ** Peak GH response to a sin

  24. Slide 24: OraGrowtH212 Patient Baseline Characteristics

    OraGrowtH212 Patient Baseline Characteristics • Mean Height SDS is lower in the 3.2 mg cohort than in the 1.6 mg cohort • 3.2 mg cohort subjects appear to be more growth hormone deficient than subjects in the 1.6 mg cohort • Differences between cohorts suggest faster growth on treatment for 3.2 mg s

  25. Slide 25: AHV Change in OraGrowtH212 Trial

    Height velocity before and after 6 months of LUM-201 administration pre-treat LUM-201 6 mo 0 4 8 12 A n n u a li z e d H e ig h t V e lo c it y ( c m /y r) 25 AHV Change in OraGrowtH212 Trial

  26. Slide 26: Mean AHV's in OraGrowtH212 Trial

    Height velocity after 6 months of LUM-201administration A n n u a li z e d H e ig h t V e lo c it y ( c m /y e a r) 7.14 cm 8.60 cm 26 Mean AHV’s in OraGrowtH212 Trial

  27. Slide 27: Durable response after 12 months of LUM-201 administration

    Durable response after 12 months of LUM-201 administration • OraGrowtH212 data demonstrate that growth acceleration is durable up to 12 months • This separate study supports the narrowing of the AHV difference seen in the 210 trial as subjects approach 12 months on treatment • A Phase 3 non-inferior

  28. Slide 28: Questions regarding the effects of LUM-201 in pediatric patients

    ▪ Does the oral administration of LUM-201 at the doses of 1.6 mg/kg or 3.2 mg/kg over 6 months increase height velocity? √ ▪ Is the change in height velocity correlated with changes in GH pulsatility? ▪ Is the increase in GH pulsatility and height velocity induced by LUM-201 dose dependent? Question

  29. Slide 29: Prior PK/PD Data Show LUM-201 Pulsatile MOA & Potential Efficacy

    Prior PK/PD Data Show LUM-201 Pulsatile MOA & Potential Efficacy in Moderate Idiopathic PGHD * Merck Study 020 patient subset. Cassorla, F. 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 0 6 12 18 24 30 Sampling Time (hr) S e ru m G ro w th H o rm o n e ( n g /m l) Patient A Baseli

  30. Slide 30: Percent change from baseline in GH AUC after 6 months of LUM-201

    Percent change from baseline in GH area under the curve (AUC) after 6-months of LUM-201 administration at doses of 1.6 or 3.2 mg/kg/day 30 LUM-201 Dose 1.6 mg/kg/day 3.2 mg/kg/day Subjects (N) 4 5 Mean Change in GH AUC from Baseline 34% 197% GH Interim Data from OraGrowtH212 Trial

  31. Slide 31: Patient 105 – 1.6 mg/kg

    Patient 105 – 1.6 mg/kg 31 Q10m 12h GH 0 200 400 600 800 0 2 4 6 8 Patient 105 Time (min) S e ru m G ro w th H o rm o n e (n g /m l) Baseline Baseline 6 months LUM-201 1.6 mg/kg/d IGF-1 (ng/ml) 110 Q10m 12h GH AUC0-12 (ng*hr/ml) 273 Height velocity (cm/yr) 4.6 Interim Data from OraGrowtH212 Trial

  32. Slide 32: Patient 105 – 1.6 mg/kg

    Baseline 6 months LUM-201 1.6 mg/kg/d IGF-1 (ng/ml) 110 185 Q10m 12h GH AUC0-12 (ng*hr/ml) 273 724 Height velocity (cm/yr) 4.6 6.8 Patient 105 – 1.6 mg/kg 32 Q10m 12h GH 0 200 400 600 800 0 2 4 6 8 Patient 105 Time (min) S e ru m G ro w th H o rm o n e (n g /m l) Baseline Month 6 Interim Data from O

  33. Slide 33: Patient 103 – 3.2 mg/kg

    Patient 103 – 3.2 mg/kg 33 Q10m 12h GH 0 200 400 600 800 0 5 10 15 Patient 103 Time (min) S e ru m G ro w th H o rm o n e (n g /m l) Baseline Baseline 6 months LUM-201 3.2 mg/kg/d IGF-1 (ng/ml) 124 Q10m 12h GH AUC0-12 (ng*hr/ml) 276 Height velocity (cm/yr) 3.4 Interim Data from OraGrowtH212 Trial

  34. Slide 34: Patient 103 – 3.2 mg/kg

    Patient 103 – 3.2 mg/kg 34 Q10m 12h GH 0 200 400 600 800 0 5 10 15 Patient 103 Time (min) S e ru m G ro w th H o rm o n e (n g /m l) Baseline Month 6 Baseline 6 months LUM-201 3.2 mg/kg/d IGF-1 (ng/ml) 124 262 Q10m 12h GH AUC0-12 (ng*hr/ml) 276 1959 Height velocity (cm/yr) 3.4 8.3 Interim Data from

  35. Slide 35: IGF-1 serum concentrations after daily LUM-201 administration in OraGrowtH212 Trial

    IGF-1 serum concentrations after daily LUM-201 administration in OraGrowtH212 Trial 35 baseline month 1 month 3 month 6 month 12 0 100 200 300 400 8 121 7 214 5 254 5 226 4 215 9 114 8 191 7 199 4 196 2 244 M e a n I G F -1 c o n c e n tr a ti o n ( n g /m L ) 1.6 mg/kg 3.2 mg/kg

  36. Slide 36: OraGrowtH212 Interim results

    - We have documented an increase in the height velocity compared to baseline in a group of prepubertal patients with moderate GH deficiency treated with two doses of LUM-201 - The improved height velocity during LUM-201 administration appears to be correlated with an increase in GH pulsatility after

  37. Slide 37: Institute of Maternal and Child Research Pediatric Team, University of Chile

    Institute of Maternal and Child Research Pediatric Team, University of Chile 37

  38. Slide 38: Rick Hawkins, CEO & Chairman Lumos Pharma, Inc.

    Rick Hawkins, CEO & Chairman Lumos Pharma, Inc.

  39. Slide 39: OraGrowtH212 & OraGrowtH210 Comparative AHVs at 6 Months

    39 OraGrowtH212 & OraGrowtH210 Comparative AHVs at 6 Months • OraGrowtH212 Trial results showed a similar growth rate to that seen in the OraGrowtH210 Trial • Anticipate fully enrolled datasets and larger N from both trials to strengthen these results • Anticipate larger Phase 3 trial to further sup

  40. Slide 40: OraGrowtH210 & OraGrowtH212 Interim Data Combined

    40 OraGrowtH210 & OraGrowtH212 Interim Data Combined • Post-hoc analysis of combined data conducted to determine optimal dose for Phase 3 • Comparable mean AHVs for top 2 LUM-201 doses seen at 6, 9, and 12 months • Combined interim data supports selection of 1.6 mg/kg/day dose for pivotal Phase 3 tr

  41. Slide 41: Interim Analysis: LUM-201 Met Expectations in Idiopathic (PEM+) PGHD

    41 Interim Analysis: LUM-201 Met Expectations in Idiopathic (PEM+) PGHD SAEs = Serious adverse events AEs = Adverse events • AHV of 8.6 cm at 6-months on 1.6 mg/kg/day LUM-201, in line with 8.3 cm expected in PEM+ PGHD • LUM-201 AHVs are sustained & converge with rhGH AHVs at 12-month treatment inte

  42. Slide 42: Questions & Answers

    Questions & Answers

Lumos Pharma — Technical Presentation (December 2022) on 6ix